BiondVax Pharmaceuticals (NASDAQ:BVXV) Coverage Initiated at

Research analysts at initiated coverage on shares of BiondVax Pharmaceuticals (NASDAQ:BVXVGet Rating) in a report released on Sunday. The firm set a “sell” rating on the stock.

BiondVax Pharmaceuticals Price Performance

NASDAQ BVXV opened at $1.00 on Friday. BiondVax Pharmaceuticals has a fifty-two week low of $0.53 and a fifty-two week high of $3.49. The stock’s 50-day moving average is $0.83 and its two-hundred day moving average is $1.10. The company has a debt-to-equity ratio of 11.62, a current ratio of 1.71 and a quick ratio of 1.71. The firm has a market cap of $14.33 million, a P/E ratio of -1.64 and a beta of 2.36.

BiondVax Pharmaceuticals’s stock is scheduled to reverse split on the morning of Friday, November 25th. The 1-10 reverse split was announced on Friday, November 25th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, November 25th.

BiondVax Pharmaceuticals (NASDAQ:BVXVGet Rating) last posted its quarterly earnings data on Thursday, August 25th. The company reported ($0.21) EPS for the quarter. On average, analysts anticipate that BiondVax Pharmaceuticals will post -0.02 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BiondVax Pharmaceuticals

A hedge fund recently raised its stake in BiondVax Pharmaceuticals stock. Envestnet Asset Management Inc. increased its position in shares of BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXVGet Rating) by 226.8% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 163,423 shares of the company’s stock after buying an additional 113,418 shares during the quarter. Envestnet Asset Management Inc. owned 1.44% of BiondVax Pharmaceuticals worth $191,000 at the end of the most recent quarter. 2.94% of the stock is owned by hedge funds and other institutional investors.

About BiondVax Pharmaceuticals

(Get Rating)

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.

Featured Stories

Receive News & Ratings for BiondVax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals and related companies with's FREE daily email newsletter.